- Home
- TFSL vs ZLAB Comparison
TFSL vs ZLAB Comparison
Compare TFSL & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TFSL
- ZLAB
- Stock Information
- Founded
- TFSL 1938
- ZLAB 2013
- Country
- TFSL United States
- ZLAB China
- Employees
- TFSL N/A
- ZLAB N/A
- Industry
- TFSL Savings Institutions
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- TFSL Finance
- ZLAB Health Care
- Exchange
- TFSL Nasdaq
- ZLAB Nasdaq
- Market Cap
- TFSL 3.9B
- ZLAB 3.2B
- IPO Year
- TFSL 2007
- ZLAB 2017
- Fundamental
- Price
- TFSL $14.21
- ZLAB $20.01
- Analyst Decision
- TFSL Hold
- ZLAB Buy
- Analyst Count
- TFSL 1
- ZLAB 6
- Target Price
- TFSL $15.00
- ZLAB $57.22
- AVG Volume (30 Days)
- TFSL 421.5K
- ZLAB 913.4K
- Earning Date
- TFSL 10-30-2025
- ZLAB 11-06-2025
- Dividend Yield
- TFSL 8.28%
- ZLAB N/A
- EPS Growth
- TFSL 14.29
- ZLAB N/A
- EPS
- TFSL 0.32
- ZLAB N/A
- Revenue
- TFSL $318,974,000.00
- ZLAB $441,629,000.00
- Revenue This Year
- TFSL $10.29
- ZLAB $40.71
- Revenue Next Year
- TFSL $3.28
- ZLAB $50.42
- P/E Ratio
- TFSL $42.66
- ZLAB N/A
- Revenue Growth
- TFSL 4.70
- ZLAB 24.14
- 52 Week Low
- TFSL $11.29
- ZLAB $19.51
- 52 Week High
- TFSL $15.00
- ZLAB $44.34
- Technical
- Relative Strength Index (RSI)
- TFSL 62.54
- ZLAB 18.89
- Support Level
- TFSL $13.21
- ZLAB $21.59
- Resistance Level
- TFSL $14.03
- ZLAB $21.00
- Average True Range (ATR)
- TFSL 0.28
- ZLAB 0.82
- MACD
- TFSL 0.02
- ZLAB -0.07
- Stochastic Oscillator
- TFSL 92.56
- ZLAB 6.52
About TFSL TFS Financial Corporation
TFS Financial Corp is the holding company for the Third Federal Savings and Loan Association of Cleveland. The company's ownership in the savings and loan association is its primary business activity. The association's principal business consists of originating and servicing residential real estate mortgage loans and attracting retail savings deposits. It does so by offering products with competitive rates and yields. The company also operates Third Capital, a wholly owned subsidiary that serves as a holding company or as an investor in vehicles such as private equity funds. Third Capital has interests in lease transactions of commercial buildings, title agencies providing escrow and settlement services, and reinsurance of private mortgage insurance on residential loans.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.